<p>关注 <strong>Immunome, Inc.</strong> (NASDAQ:IMNM) 的人无疑会对公司董事长 Clay Siegall 最近以平均每股 21.50 美元的价格购买 100 万美元股票的消息感到好奇。虽然这仅增加了他们的持股比例 5.8%，但在我们的标准下，这仍然是一个相当大的举动。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
<h2>Immunome 最近一年的内部交易</h2>
<p>值得注意的是，董事长 Clay Siegall 最近的购买并不是他们今年唯一一次购买 Immunome 股票。他们之前以每股 7.75 美元的价格购买了价值 120 万美元的股票。这种购买行为是我们所喜欢的，但这次购买的价格远低于当前的 21.44 美元。因此，这并不能告诉我们内部人士是否会觉得今天的价格具有吸引力。</p>
<p>Immunome 的内部人士在过去一年中可能购买了股票，但他们没有出售任何股票。他们的平均购买价格约为 9.38 美元。在我看来，内部人士将自己的资金投资于公司是件好事。然而，我们注意到他们的购买价格远低于今天的股价。您可以在下面看到过去 12 个月内部交易（按公司和个人）的可视化图示。如果您点击图表，可以查看所有单独的交易，包括股价、个人和日期！</p>
<p>查看我们对 Immunome 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/108518404-insider-trading-volume-1-dark-2/1766236310635?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/108518404-insider-trading-volume-1-dark-2/1766236310635"/></p>
<p>NasdaqCM:IMNM 内部交易量 2025 年 12 月 20 日</p>
<p>总是有很多股票是内部人士在购买。如果您喜欢投资不太知名的公司，可以查看这份 <strong>免费</strong> 的公司名单。（提示：内部人士一直在购买它们）。</p>
<h2>内部持股</h2>
<p>许多投资者喜欢查看公司内部人士持有多少股份。我们通常希望看到相对较高的内部持股水平。Immunome 的内部人士持有约 3800 万美元的股票。这相当于公司 2.1% 的股份。虽然这是一种强劲但并不突出的内部持股水平，但足以表明管理层与小股东之间存在一定的利益一致性。</p>
<h2>那么这些数据对 Immunome 的内部人士有什么启示？</h2>
<p>最近的内部购买令人鼓舞。我们也对内部交易的长期情况感到信心。然而，我们注意到公司在过去 12 个月内没有盈利，这让我们感到谨慎。考虑到内部人士也拥有相当多的 Immunome 股票，我们认为他们可能对未来充满信心。虽然了解内部人士的持股和交易情况是好的，但在做出任何投资决策之前，我们也确保考虑股票面临的风险。请注意，Immunome 在我们的投资分析中显示出 <strong>3 个警告信号</strong>，其中 1 个令人担忧……</p>
<p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请看看这份 <strong>免费</strong> 的有趣公司名单。</p>
<p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

IMNM

<p>Immunome, Inc.（纳斯达克代码：IMNM）的董事长 Clay Siegall 购买了 5.8% 的股份，花费了 100 万美元，平均价格为每股 21.50 美元。这是继之前以每股 7.75 美元购买 120 万美元股份之后的又一次交易。内部人士持有约 3800 万美元的股份，占公司总股份的 2.1%。尽管去年没有盈利，但内部人士的信心表明对 Immunome 的前景持积极态度</p>

<p>Those following along with <strong>Immunome, Inc.</strong> (NASDAQ:IMNM) will no doubt be intrigued by the recent purchase of shares by Clay Siegall, Chairman of the company, who spent a stonking US$1m on stock at an average price of US$21.50. While that only increased their holding size by 5.8%, it is still a big swing by our standards.</p>
<div class="lb-trans"><p>关注 <strong>Immunome, Inc.</strong> (NASDAQ:IMNM) 的人无疑会对公司董事长 Clay Siegall 最近以平均每股 21.50 美元的价格购买 100 万美元股票的消息感到好奇。虽然这仅增加了他们的持股比例 5.8%，但在我们的标准下，这仍然是一个相当大的举动。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前入场。</p>
</div><h2>Immunome Insider Transactions Over The Last Year</h2>
<div class="lb-trans"><h2>Immunome 最近一年的内部交易</h2>
</div><p>Notably, that recent purchase by Chairman Clay Siegall was not the only time they bought Immunome shares this year. They previously made an even bigger purchase of US$1.2m worth of shares at a price of US$7.75 per share. We do like to see buying, but this purchase was made at well below the current price of US$21.44. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.</p>
<div class="lb-trans"><p>值得注意的是，董事长 Clay Siegall 最近的购买并不是他们今年唯一一次购买 Immunome 股票。他们之前以每股 7.75 美元的价格购买了价值 120 万美元的股票。这种购买行为是我们所喜欢的，但这次购买的价格远低于当前的 21.44 美元。因此，这并不能告诉我们内部人士是否会觉得今天的价格具有吸引力。</p>
</div><p>Immunome insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$9.38. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!</p>
<div class="lb-trans"><p>Immunome 的内部人士在过去一年中可能购买了股票，但他们没有出售任何股票。他们的平均购买价格约为 9.38 美元。在我看来，内部人士将自己的资金投资于公司是件好事。然而，我们注意到他们的购买价格远低于今天的股价。您可以在下面看到过去 12 个月内部交易（按公司和个人）的可视化图示。如果您点击图表，可以查看所有单独的交易，包括股价、个人和日期！</p>
</div><p>Check out our latest analysis for Immunome</p>
<div class="lb-trans"><p>查看我们对 Immunome 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/108518404-insider-trading-volume-1-dark-2/1766236310635" alt="" original-src="https://images.simplywall.st/asset/chart/108518404-insider-trading-volume-1-dark-2/1766236310635"/></p>
<p>NasdaqCM:IMNM Insider Trading Volume December 20th 2025</p>
<div class="lb-trans"><p>NasdaqCM:IMNM 内部交易量 2025 年 12 月 20 日</p>
</div><p>There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this <strong>free</strong> list of companies. (Hint: insiders have been buying them).</p>
<div class="lb-trans"><p>总是有很多股票是内部人士在购买。如果您喜欢投资不太知名的公司，可以查看这份 <strong>免费</strong> 的公司名单。（提示：内部人士一直在购买它们）。</p>
</div><h2>Insider Ownership</h2>
<div class="lb-trans"><h2>内部持股</h2>
</div><p>Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Immunome insiders own about US$38m worth of shares. That equates to 2.1% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.</p>
<div class="lb-trans"><p>许多投资者喜欢查看公司内部人士持有多少股份。我们通常希望看到相对较高的内部持股水平。Immunome 的内部人士持有约 3800 万美元的股票。这相当于公司 2.1% 的股份。虽然这是一种强劲但并不突出的内部持股水平，但足以表明管理层与小股东之间存在一定的利益一致性。</p>
</div><h2>So What Does This Data Suggest About Immunome Insiders?</h2>
<div class="lb-trans"><h2>那么这些数据对 Immunome 的内部人士有什么启示？</h2>
</div><p>The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Given that insiders also own a fair bit of Immunome we think they are probably pretty confident of a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that Immunome is showing <strong>3 warning signs in our investment analysis</strong>, and 1 of those is concerning...</p>
<div class="lb-trans"><p>最近的内部购买令人鼓舞。我们也对内部交易的长期情况感到信心。然而，我们注意到公司在过去 12 个月内没有盈利，这让我们感到谨慎。考虑到内部人士也拥有相当多的 Immunome 股票，我们认为他们可能对未来充满信心。虽然了解内部人士的持股和交易情况是好的，但在做出任何投资决策之前，我们也确保考虑股票面临的风险。请注意，Immunome 在我们的投资分析中显示出 <strong>3 个警告信号</strong>，其中 1 个令人担忧……</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of interesting companies.</p>
<div class="lb-trans"><p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请看看这份 <strong>免费</strong> 的有趣公司名单。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Clay Siegall 增持了 Immunome 5.8% 的股份